ClinicalTrials.gg
TerminatedNCT01135017HESTIAUpdated Apr 11, 2013Results posted

Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers

A Phase 4 interventional study of Dronedarone and Placebo (for Dronedarone) in Atrial Fibrillation, sponsored by Sanofi. Terminated at 92 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2013-04-11.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
17th of 26
112 · median 164
Started
2010
with 8 others
Phase 4
11 of 26
2 open now
Registered
9th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 17th largest by enrollment, is one of 9 that started in 2010, is one of 11 in phase 4, and was the 9th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Primary objective was to evaluate the effects of dronedarone on Atrial Fibrillation (AF) burden (i.e. percent time in AF) as measured on electrogram (EGM) in subjects with a permanent pacemaker.

Secondary objectives were to evaluate:

  • the effects of dronedarone on AF pattern characteristics i.e. ventricular rate during AF;
  • the effects of dronedarone on subject-perceived AF burden and symptom severity as reported by subjects using the Atrial Fibrillation Severity Scale (AFSS);
  • the incidence of electrical cardioversion (or overdrive pacing) during treatment;
  • the safety of dronedarone.
Read the detailed description

The maximum duration of the study period for a participant was 18 weeks (approximatively 4.5 months) including up to 4 weeks screening, 12-week Treatment period and a post-treatment follow-up of 2 weeks.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Paroxysmal AF or atrial flutter (AFL) documented by evidence of AF/AFL and sinus rhythm within the prior 6 months;
  • AF burden ≥1% on pacemaker EGM interrogation at screening, with at least one episode of AF within the previous 28 days;
  • Programmable dual chamber pacemaker with lead placement no less than 3 months before screening, a minimum capability of storing 3 months or more of EGM data, and an expected remaining battery life of 1 year or more.

Exclusion criteria

Exclusion criteria:

  • AF burden \<1% on pacemaker EGM interrogation at screening;
  • None of the following cardiovascular risk factors: Age ≥70 years, hypertension, diabetes mellitus, prior cardiovascular accident or systemic embolism, left atrium diameter ≥50 mm by M-mode or 2D echocardiography, or ≤0.40 by M-mode or 2D echocardiography, cardiac catheterization, or nuclear cardiac imaging;
  • Permanent AF;
  • Evidence of persistent AF (continuous AF activity lasting longer than 7 days);
  • Electrical cardioversion (or overdrive pacing) within 4 weeks prior to screening;
  • Cardiac ablation procedure within 3 months prior to screening;
  • Evidence of uncorrected atrial undersensing or oversensing documented in routine pacemaker evaluation at screening;
  • Pacemaker programming requirements for the study not clinically feasible, , or could have posed risk;
  • Ongoing potentially dangerous symptoms when in AF/AFL such as angina pectoris, , stroke, or syncope;
  • (NYHA) Class IV heart failure or NYHA Class II or III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic within 4 weeks prior to screening;
  • Evidence of clinical instability including hypotension, unstable angina and hemodynamically significant obstructive valvular disease, hemodynamically significant obstructive cardiomyopathy, a cardiac operation, or revascularization procedure within 4 weeks prior to screening;
  • Noncardiovascular illness or disorder that could have precluded participation or severely limit survival including cancer with and organ transplantation requiring immune suppression;
  • Planned noncardiac or cardiac surgery or procedures including surgery for valvular heart disease, coronary artery bypass graft, percutaneous coronary intervention, cardiac transplantation or electrical cardioversion for AF/AFL;
  • Need for concomitant medication that were prohibited in this trial: Antiarrhythmics, drugs or products that are strong inhibitors of , CYP3A inducers;
  • Chronic use of amiodarone within the 4 weeks prior to screening;
  • Use of Class I or Class III antiarrhythmics (other than amiodarone) within 5-half lives prior to screening;
  • Use of St John's wort, grapefruit juice, or drugs that prolong the and might have increased the risk of torsade de pointes;
  • Inability or unwillingness to comply with oral anticoagulation therapy, if indicated;
  • Bazett corrected QT interval interval ≥500 msec at screening (if in sinus rhythm);
  • Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100mmHg) at screening;
  • Uncorrected hypokalemia (serum potassium \<3.5 mEq/L)
  • Severe hepatic impairment (ie, Class C), abnormal liver function test defined as (ALT), aspartate aminotransferase (AST), or >2 X (ULN), or renal impairment defined as serum creatinine >2.0 mg/dL at screening;
  • Uncontrolled diabetes mellitus (documented history of >10% at the most recent assessment prior to screening);
  • Pregnant woman or woman of not on adequate ;
  • Breastfeeding woman;
  • Previous (within 2 months prior to screening) or current participation in another clinical trial with an drug (under development) or investigational device.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Dronedarone

    Dronedarone 400 mg twice a day for 12 weeks

    Drug: Dronedarone

  • Placebo comparator
    Placebo

    Placebo (for Dronedarone) twice a day for 12 weeks

    Drug: Placebo (for Dronedarone)

Interventions

  • Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)

    Also known as: Multaq®, SR33589

  • DrugPlacebo (for Dronedarone)

    Film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)

06

What researchers measure

Primary outcomes

  1. Atrial Fibrillation (AF) Burden During the 12-week Treatment Period

    AF burden, defined as the percent time a subject is in AF, was evaluated centrally by a Pacemaker Core Lab based on pacemaker interrogation reports including Electrogram (EGM) data provided by the Investigator. AF burden during the 12-week treatment period was defined as the duration-weighted average of AF burden collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.

    Time frame: Baseline (before randomization), 4 weeks and 12 weeks after randomization

Secondary outcomes

  1. AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment

    AF burden at each pacemaker interrogation as evaluated centrally by the Pacemaker Core Lab

    Time frame: 4 weeks and 12 weeks after randomization

  2. Average Ventricular Rate During AF Episodes

    Ventricular rates of AF episodes were obtained from pacemaker interrogation and EGM review. The average ventricular rate during AF episodes in the 12-week treatment period was defined as the duration-weighted average of the ventricular rates collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.

    Time frame: Baseline (before randomization), 4 weeks and 12 weeks after randomization

  3. Atrial Fibrillation Severity Scale (AFSS) Scores

    The University of Toronto Atrial Fibrillation Severity Scale is an instrument to assess the subject-perceived AF burden and AF symptom severity. It consists in a questionnaire plus a scoring algorithm. AF Burden score ranges from 3 to 30 and higher scores indicate greater AF burden. AF symptoms severity score ranges from 0 to 35 and higher scores indicate extremely severe AF symptoms.

    Time frame: Baseline (before randomization) and 12 weeks after randomization

  4. Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)

    Electrical cardioversion is a procedure in which an electric shock is used to restore normal heart rhythm. Overdrive pacing is a procedure in which an artificial cardiac pacemaker is used to increase the heart rate in order to suppress certain arrhythmias. Incidence rate of electrical cardioversion (or overdrive pacing) is expressed as the number of participants that was cardioverted or paced during the study.

    Time frame: 12 weeks

Other outcomes

  1. Overview of Adverse Events (AE)

    AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.

    Time frame: from first study drug intake up to 10 days after the last study drug intake

07

Results

Posted Apr 1, 2013
Limitations and caveats
Due to smaller-than-planned number of participants (112 instead of 424), results should be cautiously interpreted. However, the power to detect large treatment effect remained high and the posthoc power to detect a 60% reduction in AF burden was 99%.

Participant flow

Recruitment initiated in July 2010 was discontinued in December, 2011 due to significantly lower than planned enrollment with no feasibility to complete the trial within reasonable, meaningful timelines and despite a protocol amendment that extended the recruitment period and reduced the sample size from 424 to 286 participants.

Participant flow — Overall Study
MilestonePlaceboDronedarone
Started5557
Treated5557
Evaluable for efficacy5555
Completed4945
Not completed612
Withdrew: Adverse event38
Withdrew: Other than above34

Outcome measures

PrimaryAtrial Fibrillation (AF) Burden During the 12-week Treatment Period

AF burden, defined as the percent time a subject is in AF, was evaluated centrally by a Pacemaker Core Lab based on pacemaker interrogation reports including Electrogram (EGM) data provided by the Investigator. AF burden during the 12-week treatment period was defined as the duration-weighted average of AF burden collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.

Time frame:
Baseline (before randomization), 4 weeks and 12 weeks after randomization
Reported as:
Geometric mean · percent time in AF
Atrial Fibrillation (AF) Burden During the 12-week Treatment Period
percent time in AFPlaceboDronedarone
Baseline8.77 (6.413 to 12.006)10.14 (7.167 to 14.354)
12-week treatment period9.90 (6.633 to 14.772)4.63 (2.610 to 8.198)
Statistical analysis
  • Placebo vs Dronedarone · ANCOVA · p = 0.0015 (No adjustment for multiplicity was made. The priori threshold for statistical significance was ≤0.05.) · Least squares (ls) mean difference: -59.13 · 95% CI -76.322 to -29.457Percent change in AF burden with dronedarone relative to placebo LS Mean difference from the ANCOVA model on log-transformed AF burden data was exponentiated to convert back to percent change.
SecondaryAF Burden During the First 4 Weeks of Treatment and After 4-week Treatment

AF burden at each pacemaker interrogation as evaluated centrally by the Pacemaker Core Lab

Time frame:
4 weeks and 12 weeks after randomization
Reported as:
Geometric mean · percent time in AF
AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment
percent time in AFPlaceboDronedarone
Week 1 - 4 (n =54, 49)8.99 (5.901 to 13.705)3.62 (1.806 to 7.258)
Week 5 - 12 (n =54, 54)9.37 (5.938 to 14.786)4.28 (2.388 to 7.673)
SecondaryAverage Ventricular Rate During AF Episodes

Ventricular rates of AF episodes were obtained from pacemaker interrogation and EGM review. The average ventricular rate during AF episodes in the 12-week treatment period was defined as the duration-weighted average of the ventricular rates collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.

Time frame:
Baseline (before randomization), 4 weeks and 12 weeks after randomization
Reported as:
Mean · beats/min
Average Ventricular Rate During AF Episodes
beats/minPlaceboDronedarone
Baseline (n =49, 47)93.02 ± 16.7490.68 ± 19.80
Week 1-12 (n =49, 48)95.67 ± 17.4391.28 ± 20.30
--- Week 1-4 (n =44, 41)96.80 ± 20.0991.93 ± 21.89
--- Week 5-12 (n =47, 42)95.58 ± 18.7288.56 ± 20.69
SecondaryAtrial Fibrillation Severity Scale (AFSS) Scores

The University of Toronto Atrial Fibrillation Severity Scale is an instrument to assess the subject-perceived AF burden and AF symptom severity. It consists in a questionnaire plus a scoring algorithm. AF Burden score ranges from 3 to 30 and higher scores indicate greater AF burden. AF symptoms severity score ranges from 0 to 35 and higher scores indicate extremely severe AF symptoms.

Time frame:
Baseline (before randomization) and 12 weeks after randomization
Reported as:
Mean · units on a scale
Atrial Fibrillation Severity Scale (AFSS) Scores
units on a scalePlaceboDronedarone
AF burden at baseline (n =45, 34)13.72 ± 4.5912.76 ± 4.62
AF burden after 12-week treatment (n =38, 31)13.30 ± 5.4012.48 ± 5.45
AF symptoms at baseline (n =55, 55)8.47 ± 6.978.36 ± 6.83
AF symptoms after 12-week treatment (n =54, 53)8.06 ± 7.117.42 ± 7.48
SecondaryIncidence Rate of Electrical Cardioversion (or Overdrive Pacing)

Electrical cardioversion is a procedure in which an electric shock is used to restore normal heart rhythm. Overdrive pacing is a procedure in which an artificial cardiac pacemaker is used to increase the heart rate in order to suppress certain arrhythmias. Incidence rate of electrical cardioversion (or overdrive pacing) is expressed as the number of participants that was cardioverted or paced during the study.

Time frame:
12 weeks
Reported as:
Number · participants
Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)
participantsPlaceboDronedarone
Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)10
Other pre-specifiedOverview of Adverse Events (AE)

AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.

Time frame:
from first study drug intake up to 10 days after the last study drug intake
Reported as:
Number · participants
Overview of Adverse Events (AE)
participantsPlaceboDronedarone
Any AE3137
- Any serious AE77
- Any AE leading to death00
- Any AE leading to treatment discontinuation38

Adverse events

Collected over All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug in the period spanning from signature of the Informed Consent Form up to the last visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/55 (12.7%)9/55 (16.4%)
Dronedarone—7/57 (12.3%)16/57 (28.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboDronedarone
Cardiac failure congestiveCardiac disorders0/553/57
Lobar pneumoniaInfections and infestations1/550/57
Intracardiac thrombusCardiac disorders1/550/57
AsthmaRespiratory, thoracic and mediastinal disorders1/550/57
DiarrhoeaGastrointestinal disorders1/550/57
MelaenaGastrointestinal disorders1/550/57
ArthralgiaMusculoskeletal and connective tissue disorders1/550/57
Non-cardiac chest painGeneral disorders1/550/57
Neuropathy peripheralNervous system disorders0/551/57
PresyncopeNervous system disorders0/551/57
Most frequent other events
Most frequent other events
EventPlaceboDronedarone
DiarrhoeaGastrointestinal disorders4/557/57
NauseaGastrointestinal disorders1/557/57
DyspnoeaRespiratory, thoracic and mediastinal disorders3/552/57
DizzinessNervous system disorders2/553/57
FatigueGeneral disorders1/553/57

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboDronedaroneTotal
Mean74.5 ± 9.577.3 ± 8.675.9 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDronedaroneTotal
Female172845
Male382967
08

Study locations

92 sites
  • Investigational Site Number 840015
    Birmingham, Alabama 35235, United States
  • Investigational Site Number 840087
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840018
    Mobile, Alabama 36608, United States
  • Investigational Site Number 840030
    Mesa, Arizona 85206, United States
  • Investigational Site Number 840048
    Phoenix, Arizona 85006, United States
  • Investigational Site Number 840072
    Phoenix, Arizona 85032, United States
  • Investigational Site Number 840013
    Tucson, Arizona 85723, United States
  • Investigational Site Number 840069
    Hot Springs, Arkansas 71913, United States
  • Investigational Site Number 840121
    Beverly Hills, California 90211, United States
  • Investigational Site Number 840090
    Laguna Hills, California 92653, United States
  • Investigational Site Number 840068
    Los Angeles, California 90048, United States
  • Investigational Site Number 840062
    Mission Hills, California 91345, United States
  • Investigational Site Number 840070
    Orange, California 92868, United States
  • Investigational Site Number 840021
    Riverside, California 92501, United States
  • Investigational Site Number 840024
    San Diego, California 92103, United States
  • Investigational Site Number 840001
    Aurora, Colorado 80012, United States
  • Investigational Site Number 840089
    Littleton, Colorado 80120, United States
  • Investigational Site Number 840029
    Loveland, Colorado 80538, United States
  • Investigational Site Number 840108
    Newark, Delaware 19713, United States
  • Investigational Site Number 840045
    Washington, District of Columbia 20010-2975, United States
  • Investigational Site Number 840106
    Washington, District of Columbia 20037, United States
  • Investigational Site Number 840010
    Clearwater, Florida 33756, United States
  • Investigational Site Number 840020
    Ft. Myers, Florida 33908, United States
  • Investigational Site Number 840058
    Inverness, Florida 34452, United States
  • Investigational Site Number 840044
    Jacksonville Beach, Florida 32250, United States
  • Investigational Site Number 840043
    Jacksonville, Florida 32204, United States
  • Investigational Site Number 840066
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840128
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840042
    Orlando, Florida 32803, United States
  • Investigational Site Number 840016
    Port Charlotte, Florida 33952, United States
  • Investigational Site Number 840080
    Wellington, Florida 33449, United States
  • Investigational Site Number 840056
    Gainesville, Georgia 30501, United States
  • Investigational Site Number 840092
    Normal, Illinois 61761, United States
  • Investigational Site Number 840032
    Oak Lawn, Illinois 60453, United States
  • Investigational Site Number 840046
    Rockford, Illinois 61107, United States
  • Investigational Site Number 840051
    Bloomington, Indiana 47403, United States
  • Investigational Site Number 840053
    Kansas City, Kansas 66160, United States
  • Investigational Site Number 840110
    Owensboro, Kentucky 42303, United States
  • Investigational Site Number 840102
    Columbia, Maryland 21044, United States
  • Investigational Site Number 840017
    Lansing, Michigan 48910, United States
  • Investigational Site Number 840081
    Lapeer, Michigan 48446, United States
  • Investigational Site Number 840075
    Petoskey, Michigan 49770, United States
  • Investigational Site Number 840027
    Troy, Michigan 48085, United States
  • Investigational Site Number 840104
    St Cloud, Minnesota 56301, United States
  • Investigational Site Number 840097
    Tupelo, Mississippi 38801, United States
  • Investigational Site Number 840037
    Columbia, Missouri 65212, United States
  • Investigational Site Number 840035
    Kansas City, Missouri 64111, United States
  • Investigational Site Number 840060
    St Louis, Missouri 63122, United States
  • Investigational Site Number 840055
    St. Louis, Missouri 63141, United States
  • Investigational Site Number 840067
    Missoula, Montana 59802, United States
  • Investigational Site Number 840049
    Reno, Nevada 89502, United States
  • Investigational Site Number 840054
    Reno, Nevada 89502, United States
  • Investigational Site Number 840026
    Bridgewater, New Jersey 08807, United States
  • Investigational Site Number 840093
    Englewood, New Jersey 07631, United States
  • Investigational Site Number 840036
    Bronx, New York 10467, United States
  • Investigational Site Number 840006
    Buffalo, New York 14215, United States
  • Investigational Site Number 840077
    Kingston, New York 12401, United States
  • Investigational Site Number 840096
    Mineola, New York 11501, United States
  • Investigational Site Number 840041
    Syracuse, New York 13202, United States
  • Investigational Site Number 840086
    Troy, New York 12180, United States
  • Investigational Site Number 840007
    Williamsville, New York 14221, United States
  • Investigational Site Number 840084
    Raleigh, North Carolina 27610, United States
  • Investigational Site Number 840061
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 840065
    Tulsa, Oklahoma 74104, United States
  • Investigational Site Number 840008
    Camp Hill, Pennsylvania 17011, United States
  • Investigational Site Number 840009
    Doylestown, Pennsylvania 18901, United States
  • Investigational Site Number 840004
    Philadelphia, Pennsylvania 19111, United States
  • Investigational Site Number 840078
    Phoenixville, Pennsylvania 19460, United States
  • Investigational Site Number 840105
    Pittsburgh, Pennsylvania 15236, United States
  • Investigational Site Number 840130
    Scranton, Pennsylvania 18510, United States
  • Investigational Site Number 840019
    Unionville, Pennsylvania 15401, United States
  • Investigational Site Number 840023
    Wyomissing, Pennsylvania 19610, United States
  • Investigational Site Number 840119
    Greenville, South Carolina 29607, United States
  • Investigational Site Number 840002
    Rapid City, South Dakota 57701, United States
  • Investigational Site Number 840114
    Germantown, Tennessee 38138, United States
  • Investigational Site Number 840118
    Corpus Christi, Texas 78404, United States
  • Investigational Site Number 840014
    Dallas, Texas 75390-8858, United States
  • Investigational Site Number 840012
    San Antonio, Texas 78229, United States
  • Investigational Site Number 840125
    Tyler, Texas 75701, United States
  • Investigational Site Number 840083
    Salt Lake City, Utah 84102, United States
  • Investigational Site Number 840113
    Danville, Virginia 24541, United States
  • Investigational Site Number 840082
    Lynchburg, Virginia 24501, United States
  • Investigational Site Number 840088
    Manassas, Virginia 20109, United States
  • Investigational Site Number 840099
    Richmond, Virginia 23219, United States
  • Investigational Site Number 840112
    Richmond, Virginia 23230, United States
  • Investigational Site Number 840003
    Tacoma, Washington 98405, United States
  • Investigational Site Number 840107
    Tacoma, Washington 98405, United States
  • Investigational Site Number 840123
    Green Bay, Wisconsin 54301-3505, United States
  • Investigational Site Number 840022
    Madison, Wisconsin 53713, United States
  • Investigational Site Number 840033
    Milwaukee, Wisconsin 53215, United States
  • Investigational Site Number 840047
    Milwaukee, Wisconsin 53215, United States
  • Investigational Site Number 840076
    Milwaukee, Wisconsin 53226, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2010
First posted
Jun 2, 2010
Start
Jul 2010
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Apr 1, 2013
Last update
Apr 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01135017
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 2, 2010
Start date
Jul 2010
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Apr 1, 2013
Last update
Apr 11, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion